TD-0903, an inhaled JAK inhibitor in development for COVID-19, blocks ARDS-relevant hyperinflammation and lung injury in primary human immune and airway epithelial cells
R. Sana (South San Francisco, United States of America), E. Gordon (South San Francisco, United States of America), A. Navratil (South San Francisco, United States of America), E. Sandvik (South San Francisco, United States of America), J. Woo (South San Francisco, United States of America), R. Saggar (South San Francisco, United States of America), E. Moran (South San Francisco, United States of America), E. Kaufman (South San Francisco, United States of America)
Source: Virtual Congress 2021 – Emerging respiratory diseases: state-of-the-art studies of SARS-CoV-2 infection
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Sana (South San Francisco, United States of America), E. Gordon (South San Francisco, United States of America), A. Navratil (South San Francisco, United States of America), E. Sandvik (South San Francisco, United States of America), J. Woo (South San Francisco, United States of America), R. Saggar (South San Francisco, United States of America), E. Moran (South San Francisco, United States of America), E. Kaufman (South San Francisco, United States of America). TD-0903, an inhaled JAK inhibitor in development for COVID-19, blocks ARDS-relevant hyperinflammation and lung injury in primary human immune and airway epithelial cells. 4304
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: